AstraZeneca (AZN)

Sector:

Pharma and Biotech

Index:

FTSE 100

12,050.00p
   
  • Change Today:
    -106.00p
  • 52 Week High: 12,178.00
  • 52 Week Low: 9,501.00
  • Currency: UK Pounds
  • Shares Issued: 1,550.24m
  • Volume: 1,635,158
  • Market Cap: £186,803m
  • RiskGrade: 123

Regulatory News

Calquence combination improved PFS in 1L MCL 02-May-2024 07:00 RNS
Total Voting Rights 01-May-2024 15:00 RNS
Truqap recommended for EU breast cancer approval 29-Apr-2024 07:05 RNS
Enhertu improved PFS in HER2-low and ultralow 29-Apr-2024 07:00 RNS
1st Quarter Results 25-Apr-2024 07:00 RNS
Result of AGM 11-Apr-2024 17:30 RNS
AstraZeneca increases 2024 dividend by 7% 11-Apr-2024 07:00 RNS
Enhertu approved in US for HER2+ solid tumours 08-Apr-2024 07:00 RNS
Imfinzi improved OS & PFS in limited-stage SCLC 05-Apr-2024 07:00 RNS
Total Voting Rights 02-Apr-2024 15:00 RNS
Voydeya approved in US 02-Apr-2024 07:05 RNS
FDA accepts Dato-DXd BLA for breast cancer 02-Apr-2024 07:00 RNS
Ultomiris approved in the US for NMOSD 25-Mar-2024 07:00 RNS
AstraZeneca to acquire Fusion 19-Mar-2024 07:00 RNS
AstraZeneca to acquire Amolyt 14-Mar-2024 07:00 RNS
 

Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: RiskGrade figures are provided by RiskMetrics.

 

AstraZeneca Market Data

Currency UK Pounds
Share Price 12,050.00p
Change Today -106.00p
% Change -0.87 %
52 Week High 12,178.00
52 Week Low 9,501.00
Volume 1,635,158
Shares Issued 1,550.24m
Market Cap £186,803m
RiskGrade 123

AstraZeneca Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
92.76% below the market average92.76% below the market average92.76% below the market average92.76% below the market average92.76% below the market average
92.16% below the sector average92.16% below the sector average92.16% below the sector average92.16% below the sector average92.16% below the sector average
Price Trend
59.45% above the market average59.45% above the market average59.45% above the market average59.45% above the market average59.45% above the market average
78.18% above the sector average78.18% above the sector average78.18% above the sector average78.18% above the sector average78.18% above the sector average
Income
92.21% below the market average92.21% below the market average92.21% below the market average92.21% below the market average92.21% below the market average
71.43% below the sector average71.43% below the sector average71.43% below the sector average71.43% below the sector average71.43% below the sector average
Growth
82.37% above the market average82.37% above the market average82.37% above the market average82.37% above the market average82.37% above the market average
94.29% above the sector average94.29% above the sector average94.29% above the sector average94.29% above the sector average94.29% above the sector average

What The Brokers Say

Strong Buy 8
Buy 15
Neutral 5
Sell 0
Strong Sell 1
Total 29
buy
Broker recommendations should not be taken as investment advice, and are provided by the authorised brokers listed on this page.

AstraZeneca Dividends

  Latest Previous
  2nd Interim 1st Interim
Ex-Div 22-Feb-24 10-Aug-23
Paid 25-Mar-24 11-Sep-23
Amount 197.00¢ 93.00¢

Trades for 03-May-2024

Time Volume / Share Price
15:21 0 @ 12,034.00p
15:21 0 @ 12,034.00p
15:17 0 @ 12,030.00p
15:17 0 @ 12,034.00p
15:15 0 @ 12,036.00p

AstraZeneca Key Personnel

Chair Michel Demare

Top of Page